Lv1
20 积分 2025-11-25 加入
Efficacy and Safety of Ivarmacitinib, a Selective JAK1 Inhibitor, in Patients With Active Ankylosing Spondylitis: Results From an Adaptive Seamless Phase 2/3 Trial
1个月前
已完结
Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial
2个月前
已完结
Fast, Present and Future of the Concept of Spondyloarthritis
3个月前
已完结
POS0262 IVARMACITINIB IMPROVES DIFFERENT DIMENSIONS OF PATIENT-REPORTED OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: A POST-HOC ANALYSIS OF A PHASE II/III TRIAL
3个月前
已关闭
Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review
3个月前
已完结
POS0803 VUNAKIZUMAB IN ACTIVE ANKYLOSING SPONDYLITIS: A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, SEAMLESS, PHASE 2/3 STUDY
3个月前
已完结
Efficacy and Safety of Ivarmacitinib, a Selective JAK1 Inhibitor, in Patients With Active Ankylosing Spondylitis: Results From an Adaptive Seamless Phase 2/3 Trial
3个月前
已完结
Low-dose interleukin-2 in the treatment of refractory relapsing polychondritis
3个月前
已完结
皖公网安备34019202002308
